MP25-07 NEUTROPHIL-TO-LYMPHOCYTE RATIO AS A PREDICTIVE BIOMARKER FOR RESPONSE TO NIVOLUMAB IN ASIAN PATIENTS WITH METASTATIC RENAL CELL CARCINOMA

INTRODUCTION AND OBJECTIVES:Nivolumab, a programmed cell death protein-1 (PD-1) antibody, is one of the most effective therapeutic agents for advanced renal cell carcinoma (RCC). Biomarkers predicting response to this treatment are needed to better select patients most likely to benefit. Neutrophil-to-lymphocyte ratio (NLR) is a prognostic and predictive biomarker in various malignancies. We sought to identify predictive markers of nivolumab response in patients with advanced RCC, including NLR.METHODS:A retrospective review was performed for 109 consecutive patients with metastatic or unresectable RCC treated with nivolumab from December 2016 to September 2018 at our institution and seven related institutions. Landmark analysis was conducted to explore the prognostic value of NLR at baseline on overall survival. Cox and logistic regression models allowed for adjustment of age, platelet count, IMDC risk classification, experience of cytoreductive nephrectomy, histological type, number of prior therapies, ...